Skip to main content

Table 3 Completed and ongoing clinical trials of anti-telomerase vaccines: current status

From: Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies

Identifier code/phase Indication Objective Start/completion date Results Sponsor/reference
NCT00510133/GRNVAC1 phase II Acute myelogenous leukemia Efficacy July 2007/August 2014 GRNVAC1 was found to be safe and well tolerated.
Positive immune responses in 55 % of patients.
Toxicity: thrombocytopenia.
Asterias Biotherapeutics (http://asteriasbiotherapeutics.com/pipeline/ast-vac1/)
NCT01579188/GV1001 phase III Non-small-cell lung cancer Efficacy May 2012/May 2016 Ongoing. Kael-GemVax
NCT00425360/GV1001 phase III Metastatic pancreatic cancer Efficacy in combination with chemotherapy September 2006/
March 2013
Adding GV1001 vaccination to chemotherapy did not improve overall survival. [108]
NCT01935154/Vx001 phase II Non-small-cell lung cancer Efficacy August 2012/
December 2016
Active. Vaxon Biotech (http://www.clinicaltrials.gov)